Bain Capital Life Sciences Investors’s Aptinyx Inc. Common Stock APTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-8,891,758
| Closed | -$1.11M | – | 34 |
|
|
2023
Q1 | $1.11M | Hold |
8,891,758
| – | – | 0.14% | 33 |
|
|
2022
Q4 | $2.54M | Hold |
8,891,758
| – | – | 0.28% | 31 |
|
|
2022
Q3 | $3.27M | Hold |
8,891,758
| – | – | 0.39% | 31 |
|
|
2022
Q2 | $4.96M | Hold |
8,891,758
| – | – | 0.58% | 28 |
|
|
2022
Q1 | $20.2M | Hold |
8,891,758
| – | – | 1.96% | 13 |
|
|
2021
Q4 | $23.7M | Hold |
8,891,758
| – | – | 1.88% | 14 |
|
|
2021
Q3 | $20.8M | Hold |
8,891,758
| – | – | 1.29% | 18 |
|
|
2021
Q2 | $25.2M | Hold |
8,891,758
| – | – | 1.65% | 15 |
|
|
2021
Q1 | $26.7M | Hold |
8,891,758
| – | – | 1.51% | 14 |
|
|
2020
Q4 | $30.8M | Buy |
8,891,758
+3,333,333
| +60% | +$11.6M | 1.93% | 13 |
|
|
2020
Q3 | $18.8M | Hold |
5,558,425
| – | – | 1.75% | 14 |
|
|
2020
Q2 | $23.2M | Hold |
5,558,425
| – | – | 2.43% | 9 |
|
|
2020
Q1 | $12M | Buy |
5,558,425
+3,333,333
| +150% | +$10.9M | 2.03% | 10 |
|
|
2019
Q4 | $7.61M | Hold |
2,225,092
| – | – | 1.13% | 10 |
|
|
2019
Q3 | $7.77M | Hold |
2,225,092
| – | – | 2% | 7 |
|
|
2019
Q2 | $7.43M | Hold |
2,225,092
| – | – | 3.78% | 5 |
|
|
2019
Q1 | $9.01M | Hold |
2,225,092
| – | – | 3.6% | 6 |
|
|
2018
Q4 | $36.8M | Hold |
2,225,092
| – | – | 12.58% | 4 |
|
|
2018
Q3 | $64.4M | Hold |
2,225,092
| – | – | 14.62% | 3 |
|
|
2018
Q2 | $53.8M | Buy |
+2,225,092
| New | +$47.6M | 16.85% | 4 |
|
Other funds holding APTX
Bain Capital Life Sciences Investors's APTX Position: Q2 2023 in Review
Bain Capital Life Sciences Investors sold out of Aptinyx Inc. Common Stock (APTX) in Q2 2023, closing a stake of 8,891,758 shares — an estimated $1.11M sold.
Bain Capital Life Sciences Investors first reported a position in APTX in Q2 2018 and held it in 20 quarters. The position peaked at $64.4M in Q3 2018. 3 funds tracked by Wall St. Rank hold APTX as of Q2 2023.
- Bain Capital Life Sciences Investors reported no remaining Aptinyx Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bain Capital Life Sciences Investors sold 8,891,758 Aptinyx Inc. Common Stock shares in Q2 2023, an estimated $1.11M.
- Bain Capital Life Sciences Investors first reported a position in Aptinyx Inc. Common Stock in Q2 2018 and held it in 20 quarters.
- Bain Capital Life Sciences Investors's Aptinyx Inc. Common Stock position peaked at $64.4M in Q3 2018.
- 3 funds tracked by Wall St. Rank held Aptinyx Inc. Common Stock as of Q2 2023.
Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2023, filed 14 Aug 2023.